Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > A few reminders from the KOL event a while back

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Mar 23, 2022 3:19pm

87 Views

Post# 34538839

RE:RE:RE:A few reminders from the KOL event a while back

All that tells us nothing about what is going on in humans. This study gives in vitro results with progranulin as the sortilin ligand, but progranulin is not TH1902, it's affinity to sortilin is not the same. Also where is this "all PDC is out of the body after two hours". We know nothing about that in humans, and TH1902 and docetaxel related to injected TH1902 are two different things. If I remember well, Marsolais was claiming that TH1902 had a half life in the bloodstream of mice of about one hour. Half life of TH1902 is not half life of docetaxel related to TH1902. And again, this was on xenografts nude mice. We have nothing about that in humans.

Wino115 wrote: It's not from their mice studies. It's from a paper they reference done by another team in a lab who were trying to find out how long sortilin took to internalize what it "scavenged" from the surface area of the cell. So, in other words, sort1 will grab the PDC and bring it into the cell in a very short time frame (but don't hold me to that interpretation as I really don't know the full extent of this lab experiment). And since the PDC is all out the body after 2 hours, the whole treatment is internalized quite rapidly, unlike an ADC that hangs around for 6-10 hours, spreading around and getting some in the tumor and some not. It's from the following slide on the KOL presentation, entitled "SORT1 Rapidly Internalizes Ligands (progranulin) Increasing Half-Life".

Here's from the paper and the reference is below. You may recognize the chart at 6E as that's what THTX used in their KOL presentation.

"Over the ensuing 10 minutes, nearly all Progranulin is removed from the cell surface of Sortilin-expressing cells. By 18 min, no diffuse plasma membrane Progranulin signal is visible, and limited signal remaining near the cell surface is concentrated in mobile puncta consistent with endosomes. The half-life for Progranulin bound to Sortilin at the cell surface is 4 min (Fig. 6E)"

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990962/

LouisW wrote: YOu mentioned "half life of TH1902 is 1 hour. " Is this in mouse? I would say that 1 hr is too shout for patients.